Fexofenadine: Approved Indications
Fexofenadine is used for treating seasonal allergic rhinitis and chronic idiopathic urticaria in adults and children 6 years and older. 1
Primary Indications
Seasonal Allergic Rhinitis
Fexofenadine effectively relieves symptoms associated with seasonal allergic rhinitis, including:
- Sneezing
- Rhinorrhea (runny nose)
- Itchy nose/palate/throat
- Itchy/watery/red eyes 1
Dosing for seasonal allergic rhinitis:
- Adults and children ≥12 years: 60 mg twice daily OR 180 mg once daily 1
- Children 6-11 years: 30 mg twice daily 1
Chronic Idiopathic Urticaria
Fexofenadine treats uncomplicated skin manifestations of chronic idiopathic urticaria by significantly reducing:
- Pruritus (itching)
- Number of wheals 1
Dosing for chronic idiopathic urticaria:
- Adults and children ≥12 years: 60 mg twice daily OR 180 mg once daily 1
- Children 6-11 years: 30 mg twice daily 1
Key Clinical Advantages
Non-Sedating Profile
Fexofenadine stands out among second-generation antihistamines as it does not cause sedation even at doses higher than FDA-approved recommendations. 2 This distinguishes it from cetirizine and intranasal azelastine, which may cause sedation at recommended doses 2
Safety in Special Populations
- Well tolerated in young children with an excellent safety profile 2
- Does not cross the blood-brain barrier, avoiding cognitive/psychomotor impairment 3
- No cardiac effects (no QT prolongation) even when combined with erythromycin or ketoconazole 3
Quality of Life Benefits
Fexofenadine significantly improves patient-reported quality of life and reduces work/activity impairment compared to placebo 4. It provides rapid symptom relief (onset ≤2 hours) with long duration of action suitable for once-daily dosing 3
Important Clinical Considerations
Renal dosing adjustments: Start with 60 mg once daily (adults) or 30 mg once daily (children 6-11 years) in patients with decreased renal function 1
Drug interactions: Avoid concurrent administration with orange or grapefruit juice as they reduce fexofenadine bioavailability 5